Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de REGN5668 administrado em combinação com Cemiplimabe ou REGN4018 em mulheres adultas com câncer de ovário recorrente

20 de setembro de 2026 atualizado por: Regeneron Pharmaceuticals

Estudo de fase 1/2 de REGN5668 (MUC16xCD28, um biespecífico coestimulatório) administrado em combinação com Cemiplimabe ou REGN4018 (MUC16xCD3)

This study is researching an investigational drug called REGN5668 :

  • alone or,
  • combined with cemiplimab (also known as REGN2810) or,
  • combined with both cemiplimab and fianlimab (also known as REGN3767), or
  • combined with ubamatamab (also known as REGN4018), with or without sarilumab.

The main purposes of this study are to:

  • Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
  • Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus

This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.

The study is looking at several other research questions, including:

  • Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
  • To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

612

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • São Paulo, Brasil, 01509-010
        • Recrutamento
        • AC Camargo Cancer Center, Fundacao Antonio Prudente
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90619-900
        • Recrutamento
        • Centro de Pesquisa em Oncologia PUCRS
    • São Paulo
      • Barretos, São Paulo, Brasil, 14784-400
        • Recrutamento
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • Sorocaba, São Paulo, Brasil, 18065-100
        • Recrutamento
        • Unimed Sorocaba
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Bélgica, 3000
        • Recrutamento
        • Universitair Ziekenhuis Leuven
      • Girona, Espanha, 17007
        • Recrutamento
        • Institut Catala dOncologia Girona
      • Madrid, Espanha, 28040
        • Recrutamento
        • Hospital Universitario Fundacion Jimenez
      • Madrid, Espanha, 28040
        • Recrutamento
        • Ciudad Universitaria
      • Madrid, Espanha, 28041
        • Recrutamento
        • Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
    • A Coruna
      • Santiago de Compostela, A Coruna, Espanha, 15706
        • Recrutamento
        • Hospital Clinico Universitario Santiago de Compostela
    • California
      • Duarte, California, Estados Unidos, 91010
        • Recrutamento
        • City of Hope Comprehensive Cancer Center
      • Irvine, California, Estados Unidos, 92618
        • Recrutamento
        • The City of Hope Orange County Lennar Foundation Cancer Center
      • Orange, California, Estados Unidos, 92868
        • Recrutamento
        • Chao Family Comprehensive Cancer Center
    • Florida
      • Tampa, Florida, Estados Unidos, 33612
        • Concluído
        • H. Lee Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Recrutamento
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      • Chicago, Illinois, Estados Unidos, 60637
        • Recrutamento
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Recrutamento
        • Massachusetts General Hospital
      • Boston, Massachusetts, Estados Unidos, 02215
        • Recrutamento
        • Dana Farber Cancer Institute Brookline Avenue
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48201
        • Recrutamento
        • Karmanos Cancer Institute
    • New York
      • New York, New York, Estados Unidos, 10065
        • Recrutamento
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Recrutamento
        • Perelman School of Medicine at the University of Pennsylvania
    • Washington
      • Seattle, Washington, Estados Unidos, 98109
        • Recrutamento
        • Seattle Cancer Care Alliance at South Lake Union - G3630
      • Villejuif, França, 94805
        • Recrutamento
        • Institut Gustave Roussy
    • Auvergne-Rhône
      • Pierre-Bénite, Auvergne-Rhône, França, 69310
        • Recrutamento
        • Hopital Lyon Sud
    • Bourgogne-Franche-Comté
      • Dijon, Bourgogne-Franche-Comté, França, 21000
        • Recrutamento
        • Centre Georges Francois Leclerc
    • New Aquitaine
      • Bordeaux, New Aquitaine, França, 33076
        • Recrutamento
        • Institut Bergonie
    • Normandy
      • Caen, Normandy, França, 14076
        • Recrutamento
        • Centre Francois Baclesse (CFB)

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Key Inclusion Criteria:

  1. Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
  2. Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
  3. Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
  4. Has adequate organ and bone marrow function as defined in the protocol
  5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Has a life expectancy of at least 3 months
  7. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol

Key Exclusion Criteria:

  1. Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
  2. Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
  3. Prior treatment with a Mucin 16 (MUC16)-targeted therapy
  4. Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
  5. Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
  6. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
  7. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
  8. Has history of clinically significant cardiovascular disease as defined in the protocol
  9. Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Module 1

REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab

Administer per the protocol

Outros nomes:
  • ubletamig

Administer per the protocol

Outros nomes:
  • REGN2810
  • Libtayo®

Administer per the protocol

Experimental: Module 2

REGN5668 and ubamatamab

Administer per the protocol

Outros nomes:
  • ubletamig

Administer per the protocol

Outros nomes:
  • REGN4018

Administer per the protocol

Outros nomes:
  • Kevzara®

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of Dose Limiting Toxicities (DLT)
Prazo: 42 days

Dose escalation phase, Module 1

42 days
Incidence of DLTs
Prazo: 21 days post combination administration

Dose escalation phase, Module 2

21 days post combination administration
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Prazo: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of Serious Adverse Events (SAEs)
Prazo: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of deaths
Prazo: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
Prazo: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
Prazo: Through study completion, up to 5 years

Primary: Dose escalation phase

Through study completion, up to 5 years
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Prazo: Through study completion, up to 5 years

Primary: Dose expansion phase

Through study completion, up to 5 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
ORR based on RECIST 1.1
Prazo: Through study completion, up to 5 years

Dose escalation phase

Through study completion, up to 5 years
Best Overall Response (BOR) based on RECIST 1.1
Prazo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Duration Of Response (DOR) based on RECIST 1.1
Prazo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Disease Control Rate (DCR) based on RECIST 1.1
Prazo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Progression-Free Survival (PFS) based on RECIST 1.1
Prazo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Prazo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
Prazo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against REGN5668
Prazo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against ubamatamab
Prazo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against cemiplimab
Prazo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against fianlimab
Prazo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Clinical Trial Management, Regeneron Pharmaceuticals

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

8 de dezembro de 2020

Conclusão Primária (Estimado)

8 de novembro de 2028

Conclusão do estudo (Estimado)

8 de novembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

9 de outubro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de outubro de 2020

Primeira postagem (Real)

19 de outubro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

24 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Prazo de Compartilhamento de IPD

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Critérios de acesso de compartilhamento IPD

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • ANALYTIC_CODE
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever